Physician profile
Johnny C Wright
NPI 1952455370
$2,143.10
in general payments reported to CMS, 2019-2025
15 companies · $163 in 2025
The $163 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.00 · 2020: $96.05 · 2021: $316 · 2022: $444 · 2023: $431 · 2024: $604 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,198.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $915.57 | 2021-2025 | Vraylar, Ubrelvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $324.80 | 2022-2024 | Caplyta |
| Lilly USA, LLC | $291.86 | 2020-2024 | Mounjaro, Zepbound |
| Gilead Sciences, INC. | $114.62 | 2024 | Epclusa |
| Braeburn INC. | $104.71 | 2023-2025 | Brixadi |
| Allergan, INC. | $89.00 | 2019 | |
| Indivior INC. | $65.57 | 2023-2024 | Sublocade |
| Lundbeck LLC | $48.40 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $38.52 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.85 | 2023 | Xifaxan |
| Eisai INC. | $30.45 | 2021 | |
| Exact Sciences Corporation | $29.07 | 2025 | The Cologuard Plus Collection Kit |
| Vanda Pharmaceuticals INC. | $28.01 | 2025 | Fanapt |
| Amgen INC. | $14.53 | 2023 | Repatha, Otezla |
| Orexo US, INC. | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnny Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.